Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.

× No keyword cloud information.

6 in total

Review 1. Leukemia secondary to myeloproliferative neoplasms.

Authors: Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal: Blood Date: 2020-07-02 Impact factor: 22.113

Review 2. Genomics of MPN progression.

Authors: Anand A Patel; Olatoyosi Odenike
Journal: Hematology Am Soc Hematol Educ Program Date: 2020-12-04

3. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2^V617F and ASXL1 mutations.

Authors: Jiajia Yuan; Junzhe Song; Chao Chen; Xue Lv; Jie Bai; Jing Yang; Yuan Zhou
Journal: Invest New Drugs Date: 2022-08-31 Impact factor: 3.651

Review 4. Accelerated Phase of Myeloproliferative Neoplasms.

Authors: Omar A Shahin; Helen T Chifotides; Prithviraj Bose; Lucia Masarova; Srdan Verstovsek
Journal: Acta Haematol Date: 2021-04-21 Impact factor: 2.195

5. A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.

Authors: Wenbin Xiao; Linde A Miles; Robert L Bowman; Vidushi Durani; Helen S Tian; Nicole L DelGaudio; Tanmay Mishra; Menglei Zhu; Yanming Zhang; Sarah E Stump; Martin S Tallman; Ross L Levine; Sheng F Cai
Journal: Blood Adv Date: 2020-12-08

6. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.

Authors: Helen T Chifotides; Lucia Masarova; Mansour Alfayez; Naval Daver; Yesid Alvarado; Elias Jabbour; Marina Konopleva; Hagop M Kantarjian; Keyur P Patel; Courtney D DiNardo; Srdan Verstovsek
Journal: Blood Adv Date: 2020-11-10